 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Clinical data | |
| Trade names | Kadcyla |
| Other names | Ado-trastuzumab emtansine, trastuzumab-DM1, T-DM1 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a613031 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antibody-drug conjugate[2] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | 93% (in vitro) |
| Metabolism | Liver (CYP3A4/3A5-mediated) |
| Elimination half-life | 4 days |
| Chemical and physical data | |
| Formula | C6448H9948N1720O2012S44·(C47H62ClN4O13S)n |
| Molar mass | 148.5 kg/mol |
  (what is this?) (verify) | |
Trastuzumab emtansine, sold under the trade name Kadcyla, is a medication used to treat breast cancer.[4] Specifically it is used for HER2 positive which have been treated with other medications.[3] It improved overall survival from 25 months to 31 months.[4] It is given by injection into a vein.[3]
Common side effects include tiredness, nausea, liver problems, bleeding, muscle pain, and constipation.[3] Other side effects may include lung problems, infusion reactions, and neurological problems.[3] Use in pregnancy may harm the baby.[5] It is an antibody-drug conjugate.[2] It consists of the monoclonal antibody trastuzumab that binds to HER2 linked to the cytotoxic agent DM1.[4]
Trastuzumab emtansine was approved for medical use in the United States and Europe in 2013.[3][4] In the United Kingdom the dose for a 70 kg person costs the NHS about £4,300 every 3 weeks as of 2021.[6] This amount in the United States is about 9,400 USD.[7]
References edit
- ^ Use During Pregnancy and Breastfeeding
- ^ a b "NCI". www.cancer.gov. 2 February 2011. Archived from the original on 3 March 2021. Retrieved 13 January 2022.
- ^ a b c d e f g h "Kadcyla- ado-trastuzumab emtansine injection, powder, lyophilized, for solution". DailyMed. 16 May 2019. Archived from the original on 4 August 2020. Retrieved 4 December 2019.
- ^ a b c d e "Kadcyla". Archived from the original on 29 April 2021. Retrieved 13 January 2022.
- ^ "Ado-trastuzumab emtansine (Kadcyla) Use During Pregnancy". Drugs.com. Archived from the original on 25 January 2021. Retrieved 13 January 2022.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 931. ISBN 978-0857114105.
- ^ "Kadcyla Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 9 February 2018. Retrieved 13 January 2022.